M&A Deal Summary

Genentech Acquires Tanox

On November 9, 2006, Genentech acquired life science company Tanox for 919M USD

Acquisition Highlights
  • This is Genentech’s 1st transaction in the Life Science sector.
  • This is Genentech’s largest (disclosed) transaction.
  • This is Genentech’s 1st transaction in the United States.
  • This is Genentech’s 1st transaction in Texas.

M&A Deal Summary
Date 2006-11-09
Target Tanox
Sector Life Science
Buyer(s) Genentech
Deal Type Add-on Acquisition
Deal Value 919M USD

Target

Tanox

Houston, Texas, United States
website
Tanox is a biotechnology company specializing in the development of monoclonal antibodies. The company develops innovative biotherapeutics for the treatment of immune-mediated diseases, inflammation, infectious disease and cancer. Tanox's lead investigational therapy, TNX-355, is a viral-entry inhibitor antibody to treat HIV/AIDS. TNX-355 has shown significant antiviral activity in Phase 2 clinical testing. Tanox's first-approved drug, Xolair® (omalizumab), is the first antibody approved to treat moderate-to-severe confirmed, allergic asthma.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genentech

San Francisco, California, United States

website

Category Company
Founded 1976
Sector Life Science
DESCRIPTION

Genentech is a biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The Company is based in San Francisco.

DEAL STATS #
Overall 1 of 3
Sector (Life Science) 1 of 3
Type (Add-on Acquisition) 1 of 3
State (Texas) 1 of 1
Country (United States) 1 of 3
Year (2006) 1 of 1
Size (of disclosed) 1 of 2
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-01 Seragon Pharmaceuticals

San Diego, California, United States

Founded in 2013, Seragon is focused on the development of selective estrogen receptor degraders (SERDs) for hormone receptor-driven cancers. SERDs are designed to bind the estrogen receptor and function as antagonists, and to induce conformational changes that may result in degradation of the receptor itself.

Buy $725M
Mergr

Product

Company

Legal